|
1. Biologie
|
|
|
|
Best treatment option written in cancer’s genetic script [Sanger Institute]
|
|
|
|
|
|
They
built a knowledge bank using data from 1,540 patients with AML who
participated in clinical trials in Germany and Austria, combining
information on genetic features, treatment schedule and outcome for each
person. From this, the team developed a tool that shows how the
experience captured in the knowledge bank could be used to provide
personalised information about the best treatment options for a new
patient.
|
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.12 Immunothérapies
|
|
|
Immuno-Oncology
Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune
Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung,
Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022 [Report Linker]
|
|
|
|
|
|
Primarily,
the Immuno-oncology market is dominated by Lung Cancer & Melanoma
applications with several companies and academic institutions focusing
on novel treatment approaches, thus making the major contribution to the
global immuno-oncology market.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
Merck in $230 million swoop for Vertex cancer programmes [Pharmafile]
|
|
|
|
|
|
Merck
has completed a deal with Boston-based biotech firm Vertex
Pharmaceuticals for the rights to four cancer programmes worth $230
million. Two of the four are clinical trial stage programmes and the
remaining two are in preclinical development. The deal bolsters Merck’s
oncology pipeline, an area that Merck have keen to strengthen as part of
a wider R&D push.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
Donald Trump and Peter Thiel vs. the FDA: Be afraid. Be very afraid. [Science-Based Medicine]
|
|
|
|
|
|
Donald
Trump’s three most likely picks for FDA Commissioner all favor
loosening drug approval standards. Two are cronies of Peter Thiel, of
which one believes that the FDA shouldn’t require evidence of efficacy,
only safety, and the other believes that a “Yelp for drugs” would do a
better job than the FDA. The third candidate is a bona fide,
honest-to-goodness pharma shill. If any of them becomes FDA
Commissioner, drug safety standards will take a nosedive.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
Pre-IMPAKT 2017 Training Course [ESMO]
|
|
|
|
|
|
Designed
by Drs. Christine Desmedt, Fabrice André, Peter Schmid and Bruno Sinn,
the course is dedicated to young, early-career oncologists, pathologists
and basic science PhD students, providing them with an understanding of
key topics of translational research that are relevant to patient care
in breast cancer.
|
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.4 Médico-éco
|
|
|